SCHEMBL23218599

SCHEMBL23218599

CCOC(=O)Cc1ccc(C(F)(F)F)cc1OCc1coc2c(OC)cc(-c3cccc(CN)c3)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 4/20 0.41
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38
F11 P03951 1/20 0.38
KLKB1 P03952 1/20 0.38
F7 P08709 1/20 0.38
TPSB2 P20231 1/20 0.38
RXRA P19793 1/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
MRGPRX4 Q96LA9 2/20 0.37
DPP4 P27487 2/20 0.35
SYK P43405 3/20 0.35
ESRRA P11474 2/20 0.35
SLC26A3 P40879 1/20 0.35
FFAR1 O14842 1/20 0.34
FFAR2 O15552 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
ICMT O60725 1/20 0.34
PTPN1 P18031 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852648 1.00 CFD (0.41) CFDPLGPLAUF11KLKB1
SCHEMBL23218180 0.91 CFD (0.48) CFDPLGPLAUF11KLKB1
SCHEMBL29592528 0.91 CFD (0.48) CFDPLGPLAUF11KLKB1
SCHEMBL29852399 0.90 CFD (0.43) CFDPLGPLAUF11KLKB1
SCHEMBL23218457 0.90 CFD (0.43) CFDPLGPLAUF11KLKB1
SCHEMBL23218408 0.89 CFD (0.42) CFDPLGPLAUF11KLKB1
SCHEMBL29852732 0.89 CFD (0.42) CFDPLGPLAUF11KLKB1
SCHEMBL23218523 0.88 CFD (0.51) CFDPLGPLAUF11KLKB1
SCHEMBL29852801 0.88 CFD (0.51) CFDPLGPLAUF11KLKB1
SCHEMBL23218252 0.88 CFD (0.42) CFDPLGPLAUF11KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885PLG 421/4885PLAU 1119/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885PLG 89/4885PLAU 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.